Phase 3 N=456 Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria
Malaria
Primary: Crude Cure Rate on Day 14 — 217; 209; 75; 73 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=148 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy
Polymyositis · Dermatomyositis · Autoimmune Necrotizing Myopathy
Primary: Number of Participants Achieving International Myositis Assessment and Clinical Studies Definition of Improvement (IMACS DOI) at Week 24 Without Rescue — 42; 31…
Phase 3 N=1,271 Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients
Falciparum Malaria
Primary: Percentage of Subjects With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28 — 99.2; 98.1 percentage of subjects — p=0.106
Phase 3 N=944 Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 154; 626; 39; 147 Participants
Phase 3 N=91 A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)
Posttraumatic Stress Disorder
Primary: Change From Baseline to Primary Endpoint in Clinician Administered PTSD Scale for DSM-V (CAPS-5) — -24.5; -12.64 score on a scale
Phase 3 N=507 Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer
Refractory Metastatic Gastric Cancer
Primary: Overall Survival (OS) — 5.7; 3.6 months — p=0.0003
Phase 3 N=44 Antibacterial Effect of Nano Silver Fluoride vs Chlorhexidine on Occlusal Carious Molars Treated With Partial Caries Removal Technique
Dental Caries
Primary: Bacterial Count of Streptococus Mutans — 2.00; 2.04; 1.12; 1.05 CFU/ml log10
Phase 3 N=204 Adjuvant HIPEC in High Risk Colon Cancer
Colorectal Neoplasms · Peritoneal Neoplasms
Primary: Peritoneal Recurrence Free Survival at 18 Months — 79; 80 participants
Phase 3 N=123 A Physical Dependence Study in Schizophrenia
Schizophrenia
Primary: Maximum 3-Day Moving Average (MA) of the Discontinuation Symptom Checklist-Modified Rickels Total Score — 13.23; 11.50 units on a scale — p=0.170
Phase 3 N=3 Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting
Nervous System Diseases
Primary: Efficacy: Number of Participants With Therapeutic Success — 3 Participants
Phase 3 N=276 Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)
Ulcerative Colitis
Primary: Proportion of Subjects With Remission at Month 6 — 82; 67 Participants — p=>0.05
Phase 3 N=651 A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer
Non-squamous Non-small Cell Lung Cancer
Primary: Overall Response Rate — 156; 145 Participants
Phase 3 N=12,460 A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine
Influenza
Primary: Number of Participants With qRT-PCR or Culture-confirmed Influenza-like Illness — 160; 138; 74; 60 Participants
Phase 3 N=568 Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)
Carcinoma, Non-Small-Cell Lung
Primary: Overall Survival (OS) — 21.4; 21.9 Months — p=0.74156
Phase 3 N=7 Ciclosporin in HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)
HTLV I Associated Myelopathy
Primary: Number of Patient With Lack of Objective Clinical Improvement — 0 Participants